Literature DB >> 15150071

Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: a case-control study with 15-year follow-up.

Barbara Susnik1, Snjezana Frkovic-Grazio, Matej Bracko.   

Abstract

BACKGROUND: The prognostic significance of occult axillary metastases was evaluated in patients with stage I breast cancer.
METHODS: Ninety-six patients with pT1 breast carcinoma who underwent axillary lymph node dissection had negative nodes in routine microscopic examination. Forty-eight patients developed distant metastases within 15 years after surgery (M group) and are compared to 48 age-matched patients who were disease-free for 15 years (NM group). We reexamined 1539 lymph nodes from these patients, using three levels and cytokeratin immunostain.
RESULTS: Occult metastases were detected in 21 patients: 16 of 48 (34%) in the M group and 5 of 48 (11%) in the NM group (P =.007). All metastases measured 2.0 mm or less and were classified as micrometastases (>0.2 mm to 2.0 mm) in 11 cases and as individual tumor cells (individual cells or clusters measuring < or =0.2 mm) in 10 cases. Micrometastases were 10 times more frequent in the M group than in the NM group (10/48 vs. 1/48; P =.004). Although there was no difference in tumor size, histologic type, estrogen receptor status, or type of treatment between the two patient groups, tumors in the M group were of a higher grade, had higher mitotic index and showed lymphovascular invasion. In multiple logistic regression, only high mitotic index and presence of micrometastases showed an independent significant correlation with the subsequent occurrence of distant metastases.
CONCLUSIONS: The presence of micrometastases (>0.2 to 2.0 mm) in axillary nodes is significantly associated with the development of distant metastases in patients with T1 breast cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15150071     DOI: 10.1245/ASO.2004.10.021

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

2.  Vascular Targeting of a Gold Nanoparticle to Breast Cancer Metastasis.

Authors:  Pubudu M Peiris; Partha Deb; Elizabeth Doolittle; Gilad Doron; Amy Goldberg; Priya Govender; Shruti Shah; Swetha Rao; Sarah Carbone; Thomas Cotey; Meilyn Sylvestre; Sohaj Singh; William P Schiemann; Zhenghong Lee; Efstathios Karathanasis
Journal:  J Pharm Sci       Date:  2015-06-02       Impact factor: 3.534

Review 3.  Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy.

Authors:  Noriaki Wada; Shigeru Imoto
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

4.  The sentinel node in breast cancer: an update.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

5.  Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Authors:  Hélène Bonsang-Kitzis; Delphine Mouttet-Boizat; Eugénie Guillot; Jean-Guillaume Feron; Virginie Fourchotte; Séverine Alran; Jean-Yves Pierga; Paul Cottu; Florence Lerebours; Denise Stevens; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; François Campana; Roman Rouzier; Fabien Reyal
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

6.  Impact of Post-Mastectomy Radiation Therapy for Sentinel Lymph Node Micrometastases in Early-Stage Breast Cancer Patients.

Authors:  Hua Luo; Ou Ou Yang; Jun Ling He; Tian Lan
Journal:  Med Sci Monit       Date:  2022-01-30

Review 7.  The sentinel node in breast cancer.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2008-10-04       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.